The European Medicines Agency has been formally notified by Arpida A/S of its decision to withdraw its application for a centralised marketing authorisation for the medicine Mersarex (iclaprim), 12.8 mg/ml concentrate for solution for infusion. Mersarex was expected to be used for the treatment of complicated skin and soft tissue infections. The application for the marketing authorisation for Mersarex was submitted to the Agency on 25 July 2008.
